SCHEDULE: Avoro Capital Advisors Reports Zero Stake in Monte Rosa

Sentiment:

Beneficial Ownership Update 14 November 2025 9:07 AM

📋All filings for Monte Rosa Therapeutics, INC

Avoro Capital Advisors and Behzad Aghazadeh have reported a 0% beneficial ownership stake in Monte Rosa Therapeutics, Inc. as of September 30, 2025.

Worse than expectedAvoro Capital Advisors LLC and Behzad Aghazadeh reported 0% beneficial ownership, indicating a complete exit from a previously reportable stake in Monte Rosa Therapeutics, Inc. This suggests a lack of confidence or a strategic divestment by a significant institutional investor.

Summary

Avoro Capital Advisors LLC and Behzad Aghazadeh (Reporting Persons) filed an Amendment No. 5 to Schedule 13G.
As of September 30, 2025, the Reporting Persons beneficially own 0.00 shares of Monte Rosa Therapeutics, Inc. Common Stock.
This represents 0% of the class of securities.
Avoro Capital Advisors LLC is a Delaware limited liability company providing investment advisory and management services, acquiring shares solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment of a reportable stake by a significant institutional investor, which could be perceived negatively for the issuer, Monte Rosa Therapeutics, Inc.

Future Outlook

Industry Context

This filing indicates a significant institutional investor, Avoro Capital Advisors, no longer holds a reportable stake in Monte Rosa Therapeutics. In the biotech/pharma industry, changes in institutional ownership are closely watched, as they may signal a shift in investor sentiment or strategy regarding the company's prospects. A reduction to 0% suggests a complete exit from a previously reportable position.

Stakeholder Impact

Shareholders of Monte Rosa Therapeutics, Inc. may view the complete divestment by Avoro Capital Advisors as a negative signal regarding the company's future prospects or current valuation.

Key Dates

Date	Description
09/30/2025	Date of event which requires filing of this statement, indicating the reporting persons' beneficial ownership of 0%.
11/14/2025	Signature date for Avoro Capital Advisors LLC and Behzad Aghazadeh.

Recommendation

sell

The filing indicates that Avoro Capital Advisors LLC and Behzad Aghazadeh, who previously held a reportable stake, now beneficially own 0% of Monte Rosa Therapeutics, Inc. This complete divestment by a sophisticated institutional investor suggests a lack of confidence in the company's future performance or a strategic decision to reallocate capital, which typically signals a negative outlook for the stock.

Keywords

Monte Rosa Therapeutics, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, beneficial ownership, common stock, investment advisory

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.